Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"...were converting all of the cars in Thailand"!
That is a very strong statement made by Bill...and may be a bit on the grandiose side.
What happen to the comment about the 'FACTS"? Facts are only required when you are supporting the company...but any bashing is "just an opinion".
I thought you said this was a scam? So the rest is irrelevant in your eyes. Are you saying there is some substance to the company now, are you validating some of the technology and even the very existence of the company?
Competitors?
EMTA Holdings Distributor Increases Sales Over 300% to Major Truckstops
PR NEWSWIRE
Posted: 2008-08-05 09:57:13
SCOTTSDALE, Ariz., Aug. 5 /PRNewswire-FirstCall/ -- EMTA Holdings, Inc., (OTC Bulletin Board: EMHD), an energy and fuel conservation company and maker of XenTx(TM), Synergyn(TM) and other engine treatment and fuel efficiency products, today announced that its major distributor of private label Synergyn(TM) products has secured contracts with two major truck stop operating companies to supply those products nationwide. Under the distributor's private label, Synergyn(TM) products will be in at least 650 truck stops across the U.S., by August 1, 2008.
This has increased orders for Synergyn(TM) products from this distributor from several pallets to 3-7 truckloads per month. This equates to at least a 331% increase in sales for this distributor and an increase in revenues of between $150,000 to $300,000/month.
"This is a significant step forward in getting our technology into the hands of truckers at a time when they must improve engine performance and efficiency just to stay in business," commented Ed Lonergan, President/CEO of EMTA Holdings, Inc. "In addition, it validates that the Synergyn(TM) technology does have tremendous value in today's transportation industry."
Synergyn(TM) products include high-performance fuel additives, engine oils, gear lubricants and transmission fluid. Synergyn(TM) was acquired by EMTA on January 1, 2007.
About EMTA Holdings
EMTA Holdings, Inc., develops and manufactures innovative products to conserve energy, particularly for petroleum-based fuels. The Company's engine and fuel additives are marketed under the brands XenTx(TM), Synergyn(TM) and CleanBoost(TM) brands, and are sold both to commercial and retail customers. They are available from key distributors, major automotive retailers and online at http://www.emtacorp.com/store. For additional information on EMTA products, please visit http://www.xentx.com.
Forward-Looking Statements: This press release discusses certain matters that may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the intent, belief or current expectations of EMTA Corp. ("the Company") and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results such as, but not limited to: the ability of the Company to raise necessary capital; to attract and retain effective management; the lack of viable commercial applications or the failure of third-party contractors to perform their contractual obligations. Prospective investors are also referred to the other risks identified from time to time in the Company's reports and registration statement filed with the Securities and Exchange Commission.
CONTACT:
Larry Downs
Equiti-trend
Director of Communications
800-585-6988
lwdowns@equititrend.comOrPaula C. Wright
VP IR/PR/Media
EMTA Holdings, Inc.
480-222-6222
pwright@corporatearchitects.com
SOURCE EMTA Holdings, Inc.
At least it is news. However, I don't see any information about signed contracts, sales numbers, funding plans or timelines for results.
I do see a lot of information about potential, planning, strategizing, informative meetings and testing. Comments like "working on making these products available" or statements like "will be ready to launch in time for their October release of E85 around the country", but no agreement with anyone to sell it.
Is there any measureable information in the PR? There is a lot of information without really anything of substance.
If I had not owned this stock for the last 5 years, I actually might be excited about this latest PR. Best case, it is still a long way down the road, with some huge hurdles in the way.
That is pretty funny. Japonese and you are Japanese. And Makecents, you completely missed the relation between the two posters.
And both of them have the same terrible English.
Is this a small move on the price ahead of earnings over the last couple of days?
That is right...anonymous internet posters get free reign here and no one is allowed to challenge their intent or connection. But they are allowed to make personnel attacks against anyone connected with the subject. It should all be fair game. There are obvious pumpers and bashers here. Some seem to work 24/7 trying to bring down this company on this thread. Competitors, shorters, unhappy people with too much time on their hands...who knows?
So if they were to become members/posters they would be off limits. See how that theory does not work!
I think you mean employees and opinions. And that is the problem.
That is a load of crap. You say it is supposed to be about the company and not personal. So you can't questioned secret posters relationships and background, but personal deflamation of directors and management is okay? There is no difference.
Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.
Kendirgi F, Yun NE, Linde NS, Zacks MA, Smith JN, Smith JK, McMicken H, Chen Y, Paessler S.
CytoGenix, Inc., 3100 Wilcrest Dr. Suite 140, Houston, TX 77042, USA.
Vaccine development for possible influenza pandemics has been challenging. Conventional vaccines such as inactivated and live attenuated virus preparations are limited in terms of production speed and capacity. DNA vaccination has emerged as a potential alternative to conventional vaccines against influenza pandemics. In this study, we use a novel, cell-free DNA manufacturing process (synDNA(trade mark)) to produce prototype linear DNA vaccines against the influenza virus type A/H5N1. This synDNA(trade mark) process does not require bacterial fermentation, so it avoids the use of antibiotic resistance genes and other nucleic acid sequences unrelated to the antigen gene expression in the actual therapeutic DNA construct. The efficacy of various vaccines expressing the hemagglutinin and neuraminidase proteins (H5N1 synDNA(trade mark)), hemagglutinin alone (H5 synDNA(trade mark)) or neuraminidase alone (N1 synDNA(trade mark)) was evaluated in mice. Two of the constructs (H5 synDNA(trade mark) and H5N1 synDNA(trade mark)) induced a robust protective immune response with up to 93% of treated mice surviving a lethal challenge of a virulent influenza A/Vietnam/1203/04 H5N1 isolate. In combination with a potent biological activity and simplified production footprint, these characteristics make DNA vaccines prepared with our synDNA(trade mark) process highly suitable as alternatives to other vaccine preparations.
PMID: 18443425 [PubMed - as supplied by publisher]
When a president of a company is talking about "110% dedication", it makes it a little clearer why they had such problems with understanding the numbers. We should ask them why they did not give 120 or 200%?
Arnold, come on...are you that naive? If you invest $1000 in a .06 stock or a $100 stock and if it goes to zero, it is still a 100% loss. I actually thought you were smarter than that.
Skoob was flat out wrong for the first 4 years...and you think he is right now...or just switched teams?
Paulness...who was it that said they "get paid for what the know, and not for what they do"?
That is called age discrimination and it is viewed as being illegal on a federal level in the USA for such things as employment considerations and performance reviews. And most upstanding people consider it morally wrong.
So you delete every OT comment, every comment from people saying they will be gone, or wishing people Happy Thanksgiving, or have a nice weekend, or whatever. Your criteria is that if it is not about the company, period, you delete it.
Or not.
This is the question and answer board.
The board is about the company and the message.
Just got back from Vegas...did not see him.
I know the industry well and what goes on behind the curtain. As far as being antagonistic, do you read your own thread? Are you that blind to the antagonistic nature of the negative post!!!
I am sorry, are you Matt?
Matt...help...would you please check on CYGX...why would the following post be deleted?
Yes, the main reason that this board has deteriorated to the level it is today. This board used to be for investors and people interested in the well-being of the company and was run as such.
I think you missed his point.
October 2007
Dear Shareholders,
The following is a brief summary of activity during the third quarter of this fiscal year.
Management
The Company welcomes Greg Taylor as its new Chief Financial Officer. Mr. Taylor took on the responsibilities as CFO at the beginning of September and brings a strong combination of training and experience in strategic planning, business operations, financial management and fund raising to the position. Mr. Taylor's biography will be posted on the Company Website. The search for a new CEO continues and is expected to accelerate as the Company attains a stronger financial position.
Business Development
The Company has historically raised operating funding through small private placements of unregistered securities. In order to take the Company to the next level of growth, we are working to supplement this ongoing support with additional institutional financing.
In addition to supporting the completion of our new corporate and laboratory facility, this combined funding effort is designed to support the ongoing marketing and development of four of our leading products including:
the manufacture and sale of synDNA(tm) to third party users, including diagnostic, drug and vaccine developers;
preparation for IND submission to the FDA for permission to test Simplivir(tm) in clinical trials by performing toxicity and absorption, distribution, metabolism and excretion (ADME) tests;
preparation for performing ADME tests to ready pandemic flu and smallpox synDNA(tm) vaccines for IND submission;
development of other promising synDNA(tm) vaccines in collaboration with the US Army Research Institute for Infectious Diseases (USAMRIID) at Fort Detrick and in collaboration with the US Department of Agriculture; and
development of oligonucleotide based anti-microbials including methicillin resistant staphylococcus aureus (MRSA) and anti-cancer programs.
In addition, the Company has implemented an aggressive plan to submit multiple grant proposals to various government and private agencies representing the Company's development of its leading proprietary technology, including the development of synDNA(tm) vaccines and oligonucleotide-based anti-microbials.
The Company has partnered with BioXcel Corporation, which provides worldwide business services in the areas of pharmaceuticals, biotechnology, diagnostics, and associated industries. BioXcel has initiated multiple contacts and several agreements for evaluation trials for synDNA(tm) to date, and has been instrumental in raising the profile of the Company within the pharmaceutical industry both nationwide and in Europe. The Company is currently negotiating extension of this agreement to further expand its marketing efforts and to provide synDNA(tm) constructs to other companies. To complement this effort, the Company plans to hire additional marketing and business professionals in the coming year that will provide an even stronger base of experience to this effort.
Scientific Development in the third quarter, 2007
The Company's ongoing research and development efforts have previously produced three platforms which support product development: (1) cell-free production of DNA (synDNA(tm)); (2) single-stranded DNA expression systems; and (3) anti-microbial/anti-cancer oligonucleotide sequences. These areas will continue to be the focus of the Company with the goal being IND filings along with clinical trials to prove the safety and efficacy of its products. The success of these efforts will drive the value creation of CytoGenix.
Ongoing Sponsored Research
Drs. Jeffery Actor & Lisa Armitige at the University of Texas Health Science Center Houston, Texas are conducting a study entitled, "Novel compounds against Staphylococcus aureus (MRSA) and M. tuberculosis ".
Drs. Lyuba Benimetskaya and Cy Stein at Albert Einstein College of Medicine, New York are conducting a study entitled, "Targeting melanoma and prostate cancer genes".
Dr. Slobodan Paessler at University of Texas Medical Branch, Galveston, TX is conducting a study entitled "Influenza H5N1 synDNA(tm) vaccine".
Dr. David Weiner at University of Pennsylvania, Philadelphia, PA is conducting a study entitled "synDNA(tm) vaccines against HIV and smallpox in primate models".
Recent Scientific Paper Submissions
Kendirgi, F., Nadezda E. Yun, N.E, Linde, N.S., Zacks, M.A, Smith, J.N., Smith, J.K., McMicken, H., Chen, Y.*, & Paessler, S. Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1, Vaccine, 2007 (submitted).
Conference Presentations
Chen, Y. "Production of DNA Using a Novel Cell-Free synDNA™ Technology", DNA Vaccine 2007, Malaga, Spain, May 23-25, 2007 (invited speaker).
Kendirgi, F., et al., "A Novel DNA-based vaccine protects mice against lethal infection with H5N1 influenza virus isolate A/Vietnam/1203/04". Options for the control of influenza VI, Toronto, Ontario, Canada, June 17-23, 2007 (abstract).
Chen, Y., et al., "Rapid Production of DNA Vaccines Using a Novel Cell-Free synDNA™ Technology', Biomedical Advanced Research and Development Authority (BARDA)-Industry Day, Washington, DC, August 3, 2007 (invited speaker).
Chen, Y. Producing DNA Vaccines Using a Novel Non-Fermentation Technology, European Biopharm Scale-up, Geneva, Switzerland, September 11-13, 2007 (invited speaker).
Tan, X, et al., "Novel DNA Aptamers against Staphylococcus aureus Identified by Whole-Bacterium SELEX", 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, September 17-20, 2007 (abstract, winner of ICAAC Program Committee Award).
Building Progress
Following the grant of building permits by the City of Houston, which took longer than anticipated, groundbreaking for the new CytoGenix facility was held on August 30, 2007. The new site is 6030 North Course Drive located just south of Harwin between Beltway 8 (Sam Houston Tollway) and Wilcrest Drive. The foundation has now been poured and construction is proceeding on schedule with an anticipated completion of the initial phase, which consists of office and lab space, in the second quarter of 2008. Actual progress is dependent upon weather, material, sub-contractor availability and related factors. Buildout of the GMP production facility is dependent upon funding constraints but is anticipated to be completed in the forth quarter of 2008. We will post updates of site photos as progress continues.
Legal Update
Intellectual Property Matters - Since July, we have filed two additional provisional patent applications. One application covers a new set of sequences effective in animal challenge experiments against pandemic flu infection as a synDNA™ vaccine. The other covers an enrichment procedure used to identify novel sequences effective in killing specific types of antibiotic resistant bacteria. This expands our patent holdings to a total of 70 pending patents or patent applications covering various applications of our ssDNA expression, herpes antiviral, anti-bacterial and synDNA™ technology platforms. Typical patent practice routinely rejects most of the initial claims submitted to the patent office. It is only through argument with patent examiners and iterated modification of patent claims that patents able to withstand challenges are obtained.. As such, our 57 pending patent applications are proceeding through the normal prosecution process.
Waldroff and Applied Veterinary Genomics, Inc. - Litigation initiated in March 2004 regarding the validity of license agreements for use of our ssDNA expression technology in shrimp and horse therapeutic applications, which initially resulted in entry of a judgment against CytoGenix, was successfully appealed by the Company in December of 2006 with a finding that there was no obligation for CytoGenix to honor the contracts or to pay opposing party attorney fees. Waldroff and Applied Veterinary Genomics subsequently filed a motion for a rehearing which was denied by the Appellate Court. Waldroff and Applied Veterinary Genomics then filed a Petition for Review with the Texas Supreme Court which was dismissed. The case has been finalized through all available appeal proceedings in favor of CytoGenix, and a final mandate was issued by the 1st Court of Appeals on August 31, 2007. The security deposit made by the Company to comply with the trial court's judgment has been released and the funds returned to the Company.
Employment Litigation Issues - The Company continues with its ongoing arbitration effort to determine if former executives, Lawrence Wunderlich (CFO) and Frank Vazquez (COO) are entitled to benefits following their resignations from the Company in November of 2006. Following his resignation, the former CFO filed a Sarbanes-Oxley (SOX) whistleblower complaint with the Department of Labor (DOL). The SOX complaint was forwarded to the SEC which made a separate inquiry. The Company submitted answers to the original questions directed to the Company by the SEC and has further addressed the SEC inquiry by appointing a special investigative committee made up of outside directors who commissioned an independent, outside attorney to conduct an investigation to determine the merits of the allegations made in the SOX complaint. The investigation was concluded and a final report was filed with the SEC by the independent investigator on behalf of the special committee on September 5, 2007. The report included a finding that the allegations of Company malfeasance made in the SOX complaint are not supported by the evidence, are devoid of merit, and must be rejected. The Company awaits further communication from the SEC with regard to the SOX complaint as it prepares for Arbitration.
Compliance Issues - The Company is continuing the process of improving it's corporate governance provisions to include business conduct and ethics provisions as well as disclosure controls. CytoGenix, Inc. is committed to and is in the process of correcting weaknesses identified in its internal control processes.
Thank you for your ongoing interest and support.
Malcolm Skolnick
At this rate, we might even challenge the high next week.
danny: What do you base your valuation on?
Thanks.
DOMS is out, way out.
Now we are starting to pop.
No, you don't understand. It is not the person objective to make a point, only to maintain the argument.
That argument only works when you know your opponent and their intentions. When the other is arguing and they do not care about the argument, only that there is an argument, then the intent changes.
ec. Gee, if you buy it at .33 cents a share and it goes to 0, you still lost 100% of your investment. What difference does it make if you pay $90 a share or .10 cents a share?
If you spend $10,000 on a $90 stock or a .10 cent stock, you still loose it all if it goes to 0.
A lost is a loss.
That kind of thinking will get you bankrupt.
Credibility is everthing...
you have to be smart enough to know the difference between opinions and manipulation.
Yeah right...like those guys live paycheck to paycheck. You are so transparent.
No, just looked you were running an ad.
Gee pupp...it looks like you just cut and pasted an ad for them. Are you on their payroll?
No Arnold, it is called solid investing advice. No charge.
Nope, I am not a flipper or a trader...I buy for the long term. So far so good. This stock still has a lot of life left in it.